Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice

Fig. 1

Takinib reduces the clinical arthritis score. DBA/1 mice disease induced with CIA and demonstrated clinical arthritic scores around day 25, which persisted throughout the study. Mice were treated daily with vehicle control or takinib (50 mg/kg) intraperitoneal injections. Takinib-treated mice show a reduction in clinical arthritic score compared to vehicle control (a). Day 36 clinical score between takinib and vehicle treated (b). Weight change over 2 weeks of treatment (c). Overall weight change between treatment groups (d). n = 4 ± SEM/normal (vehicle) group, n = 9–12 ± SEM/vehicle disease control and takinib groups. *p < 0.05, **p < 0.01, ***p < 0.001 two-way ANOVA, Dunnett’s post hoc

Back to article page